HSN Leade​rship

Cynthia I. Campbell, PhD, MPH​

Health System Node Principal Investigator
Kaiser Permanente Division of Research

 

Dr. Cynthia Campbell is a Senior Research Scientist at the Division of Research, Kaiser Permanente Northern California, where she co-directs the Center for Addiction and Mental Health Research. She is also an Adjunct Professor in the Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, and an Associate Professor at the Bernard J. Tyson School of Medicine. With two decades of experience, Dr. Campbell's research on substance use and comorbidity leverages electronic health record data, patient surveys, and pragmatic trials. Her work focuses on access to care, pain and substance use, prescription opioids and cannabis use, and related health policies.  Dr. Campbell led a PCORI-funded trial of a patient activation intervention in primary care for patients using opioids long term, as well as a NIDA-funded trial testing differences in psychosocial service intensity for patients in substance use disorder treatment. She was the lead investigator of the Prescription Opioid Registry study (CTN-0084), which developed a multi-site prescription opioid registry based on electronic health record data across 10 health systems to address important questions on the opioid crisis. She was the co-lead investigator of the D-TECT study (CTN-0084-A-2; co-lead investigator Dr. Lisa Marsch) that was a digital phenotyping of patients receiving buprenorphine medication for opioid use disorder to establish methodological feasibility and predict relapse. Dr. Campbell also led CTN-0117, that examined pandemic related changes in substance use disorder treatment utilization, and has been a co-investigator on: HEDIS AOD-IET Measure Performance (CTN-0072-OT), the PROUD Trial (CTN-0074), Cannabis use and Pregnancy (CTN-0140), and Insurance Instability and Mortality (CTN-0141). ​

Dr. Campbell is supported by Senior Project Manager or HSN Project Director Monique Buffler. Ms. Buffler is the administrative lead contact for HSN and manages activities at Kaiser Permanente Northern California.

 

​​

Ingrid A. Binswanger, MD, MPH, MS

Health System Node Principal Investigator
Kaiser Permanente Colorado Institute for Health Research​

 

Dr. Ingrid A. Binswanger is a Senior Clinician Investigator at the Institute for Health Research, Kaiser Permanente Colorado. She is also a Professor of Medicine at the University of Colorado School of Medicine and Adjunct Professor of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. Dr. Binswanger's research focuses on preventing overdose, improving treatment provision and outcomes in health systems, and improving healthcare transitions between carceral and community settings.  Her prior work includes practice-changing studies on death after release from prison, pragmatic trials of strategies to enhance naloxone provision in health systems, and multisite studies of the intended and unintended effects of opioid tapering and discontinuation. After a decade of involvement in the NIDA CTN Health Systems Node as Site PI for Kaiser Permanente Colorado, she joined the Health Systems Node leadership team as Multiple PI in 2025. She is currently a site lead for Insurance Instability and Mortality (CTN-0141) and site PI for Office-based Methadone Trial - EMBOSS (CTN-0131). She was Co-I on the following completed CTN studies: HEDIS AOD-IET Measure Performance (CTN-0072), Evaluation of Medical Cannabis Documentation (CTN-0077), Prescription Opioid Registry (CTN-0084), and Determining Optional Duration of Buprenorphine Treatment (CTN-0084-A-1). And she was site PI for an exemplar site of the PROUD trial (CTN-0074). Dr. Binswanger is dual board-certified in internal medicine and addiction medicine. As a physician with the Colorado Permanente Medical Group, she sees patients in the Rapid Start Clinic, Chemical Dependency Treatment Services at Kaiser Permanente Colorado. ​​

​ 

 

Katharine A. Bradley, MD, MPH

Health System Node Principal Investigator
Kaiser Permanente Health Research Institute

 

Dr. Katharine Bradley is a general internist and Senior Investigator at Kaiser Permanente Washington Health Research Institute. She conducts health services research and pragmatic and implementation trials focused on improving the quality of care for patients with unhealthy alcohol and substance use in general medical settings. She previously conducted extensive research validating and implementing AUDIT-C alcohol screening questionnaire in the VA. She led the NIAAA-funded CHOICE trial that tested the effectiveness of collaborative care for alcohol use disorders in the VA and the AHRQ funded SPARC trial which was a pragmatic stepped-wedge trial to implement evidence-based care for unhealthy alcohol use in Kaiser Permanente Washington (KPWA). Dr. Bradley led the NIDA CTN funded PROUD Trial (CTN-0074), which was a pragmatic trial testing implementation of a collaborative care model for treating opioid use disorders (OUDs) in primary care across 6 geographically dispersed health systems. She is also Multiple PI on two other pragmatic trials: an NIMH-funded HEAL pragmatic trial of patient-centered, collaborative care for primary care patients with OUD and depression in KPWA and Indiana University Health System (MI-CARE trial; MPI with Dr. DeBar), and an NIAAA-funded cluster-randomized implementation trial of shared decision making with a decision aid for primary care patients with alcohol use disorder (Options Trial; MPI with Dr. Lapham). Dr. Bradley also conducts health services research on substance use in primary care, which has included Evaluation of Drug Screening Implementation (CTN-0065-OT), which evaluated a pilot study implementing cannabis and other drug screening in 3 primary care sites; Evaluation of Medical Cannabis Documentation (CTN-0077-OT; MPI with Dr. Lapham) that studied medical cannabis use in primary care patients and how that is documented in their electronic health records (EHRs), and Validating Substance Use Symptom  Checklist (CTN-0113; MPI with Dr. Williams), which used EHR data to evaluate the psychometric performance of a DSM-5 substance use symptom checklist in primary care patients with substance use. She also collaborates on the Co-CARE pragmatic trial (CTN-0139; Drs. McNeely and Liebschutz Lead Investigators).

Core Investigators

Core investigators are supported by the HSN and bring a breadth of expertise and leadership to concept and protocol development. Our core investigators bring expertise in leading trials, statistical methods, and qualitative methods.

• Andrea Altschuler, PhD
• Jennifer Bobb, PhD
• Marlaine Figueroa Gray, PhD
• Jason Glanz, PhD
• Gwen Lapham, PhD, MPH, MSW
• Komal Narwaney, PhD
• Anh Nguyen, PhD
• Joshua Nugent, PhD
• Stacy Sterling, DrPH, MSW, MPH
  
  

Affiliate investigators include additional senior investigators who can lead CTN trials, mid-career investigators with important expertise to support CTN trials, and early-stage investigators who will be mentored and collaborate in executing Node agendas. Many are embedded within affiliate health systems.